Core Insights - BioMarin Pharmaceutical is focusing on disciplined expense management and efficient cost allocations to achieve leveraged growth, expecting earnings per share growth at roughly three times revenue growth in 2025 [1] - The company anticipates "high single digits" growth for both Skeletal Conditions and Enzyme Therapies, with the planned Amicus acquisition expected to add two high-growth products [2][7] - BioMarin reported a total revenue growth of 13% in 2025, with Skeletal Conditions growing by 26% and Enzyme Therapies by 9% [3] Financial Performance - BioMarin's revenue growth in 2025 was driven by a strong performance in its Skeletal Conditions unit, which includes the product VOXZOGO [3] - The company expects continued operating margin expansion and cash flow growth alongside revenue growth [1] Strategic Initiatives - The company is executing a three-pillar strategy focused on growth, innovation, and value commitment, which includes recent revenue momentum and multiple clinical milestones [4] - The planned acquisition of Amicus is seen as a strategic move to enhance product offerings in rare genetic conditions, with expectations of slight dilution in 2026 but substantial accretion thereafter [7][14] Product Pipeline and Development - BioMarin is advancing its pipeline with key programs such as BMN 351 for Duchenne muscular dystrophy and BMN 401 for ENPP1 deficiency, with significant data expected in the near term [5][16] - The company is also developing a long-acting version of VOXZOGO, BMN 333, aimed at being superior to existing therapies [10] Market Dynamics - VOXZOGO revenue is expected to be weighted towards the second half of the year, with approximately 75% of its revenue coming from outside the U.S. [17] - The company is focusing on expanding its geographic reach and improving diagnosis rates for conditions like Fabry disease through the Amicus acquisition [13]